The renin-angiotensin-aldosterone system in patients with depression compared to controls - A sleep endocrine study

BMC Psychiatry

Volumn 3, Issue , 2003, Pages

  Murck, Harald ^b   Held, Katja ^a   Ziegenbein, Marc ^a   Künzel, Heike ^a   Koch, Kathrin ^a   Steiger, Axel ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b Laxdale Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; CHLORAL HYDRATE; CORTICOTROPIN; FLUOXETINE; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR; RENIN; VASOPRESSIN;

ADULT; AGE; AGED; ALDOSTERONE RELEASE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; COVARIANCE; DEPRESSION; DISEASE MARKER; ELECTROENCEPHALOGRAPHY; ENDOCRINOLOGY; FEMALE; HORMONAL REGULATION; HORMONE DETERMINATION; HORMONE SENSITIVITY; HUMAN; HYDROCORTISONE RELEASE; HYPERCORTISOLISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NONREM SLEEP; POLYSOMNOGRAPHY; REM SLEEP; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SLEEP; STATISTICAL ANALYSIS;

ADRENOCORTICOTROPIC HORMONE; ADULT; AGED; ALDOSTERONE; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CIRCADIAN RHYTHM; DEPRESSIVE DISORDER; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; RECEPTORS, MINERALOCORTICOID; RENIN; RENIN-ANGIOTENSIN SYSTEM; SEX FACTORS; SLEEP; SLEEP, REM;

EID: 2642513171     PISSN: 1471244X     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-244X-3-15     Document Type: Article

References (61)

1. Carroll BJ, Curtis GC and Mendels J: Cerebrospinal fluid and plasma free cortisol concentrations in depression. Psychol Med 1976, 6:235-244.
2. Maes M, Lin A, Bonaccorso S, van Hunsel F, Van Gastel A, Delmeire L, Biondi M, Bosmans E, Kenis G and Scharpe S: Increased 24-hour urinary cortisol excretion in patients with post-traumatic stress disorder and patients with major depression, but not in patients with fibromyalgia. Acta Psychiatr Scand 1998, 98:328-35.
3. Steiger A, von Bardeleben U, Herth T and Holsboer F: Sleep EEG and nocturnal secretion of cortisol and growth hormone in male patients with endogenous depression before treatment and after recovery. J Affect Disord 1989, 16:189-195.
4. Casper RC, Kocsis J, Dysken M, Stokes P, Croughan J and Maas J: Cortisol measures in primary major depressive disorder with hypersomnia or appetite increase. J Affect Disord 1988, 15:131-140.
5. Garvey MJ, Schaffer C, Schaffer L and Perry PJ: Is DST status associated with depression characteristics? J Affect Disord 1989, 16:159-165.
6. Maes M, De Ruyter M, Hobin P and Suy E: The dexamethasone suppression test, the Hamilton Depression Rating Scale and the DSM-III depression categories. J Affect Disord 1986, 10:207-214.
7. Roy A: Cortisol nonsuppression in depression: relationship to clinical variables. J Affect Disord 1988, 14:265-270.
8. Thase ME, Himmelhoch JM, Mallinger AG, Jarrett DB and Kupfer DJ: Sleep EEG and DST findings in anergic bipolar depression. Am JPsychiatry 1989, 146:329-333.
9. Antonijevic IA, Murck H, Frieboes RM, Uhr M and Steiger A: On the role of menopause for sleep-endocrine alterations associated with major depression. Psychoneuroendocrinology 2003, 28:401-18.
10. De Kloet ER, Vreugdenhil E, Oitzl MS and Joels M: Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998, 19:269-301.
11. Heuser I, Deuschle M, Weber B, Stalla GK and Holsboer F: Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone. Psychoneuroendocrinology 2000, 25:513-518.
12. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ and Akil H: Mineralocorticoid receptor function in major depression. Arch Gen Psychiatry 2003, 60:24-8.
13. Whitworth JA, Butty J, Saines D, Scoggins B and Thatcher R: The effects of ACTH on the renin-aldosterone system in normotensive man. Clin Exp Hypertens A 1985, 7:1361-1376.
14. Deuschle M, Weber B, Colla M, Muller M, Kniest A and Heuser I: Mineralocorticoid receptor also modulates basal activity of hypothalamus-pituitary-adrenocortical system in humans. Neuroendocrinology 1998, 68:355-360.
15. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ and Akil H: The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans. J Clin Endocrinol Metab 1998, 83:3339-45.
16. Born J, Steinbach D, Dodt C and Fehm HL: Blocking of central nervous mineralocorticoid receptors counteracts inhibition of pituitary-adrenal activity in human sleep. J Clin Endocrinol Metab 1997, 82:1106-1110.
17. Steiger A, Rupprecht R, Spengler D, Guldner J, Hemmeter , Rothe B, Damm K and Holsboer F.: Functional properties of deoxycorticosterone and spironolactone: molecular characterization and effects on sleep-endocrine activity. J Psychiatr Res 1993, 27:275-284.
18. Jezova D, Ochedalski T, Kiss A and Aguilera G: Brain angiotensin II modulates sympathoadrenal and hypothalamic pituitary adrenocortical activation during stress. J Neuroendocrinol 1998, 10:67-72.
19. Ganong WF: Blood, pituitary, and brain renin-angiotensin systems and regulation of secretion of anterior pituitary gland. Front Neuroendocrinol 1993, 14:233-249.
20. Baghai TC, Schüle C, Zwanzger P, Minov C, Zill P, Ella R, Eser D, Oezer S, Bondy B and Rupprecht R: Hypothalamic-pituitary-adrenocortical axis dysregulation in patients with major depression is influenced by the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene. Neurosci Lett 2002, 328:299-303.
21. Charloux A, Gronfier C, Lonsdorfer-Wolf E, Piquard F and Brandenberger G: Aldosterone release during the sleep-wake cycle in humans. Am J Physiol 1999, 276:E43-E49.
22. Van den Burg W, Beersma DG, Bouhuys AL and Van den Hoofdakker RH: Self-rated arousal concurrent with the antidepressant response to total sleep deprivation of patients with a major depressive disorder: a disinhibition hypothesis. J Sleep Res 1992, 1:211-222.
23. Coppen A: Mineral metabolism in affective disorders. Br J Psychiatry 1965, 111:1133-1142.
24. Joffe RT, Blank DW, Berrettini WH and Post RM: Erythrocyte sodium and potassium in affective illness. Acta Psychiatr Scand 1986, 73:416-419.
25. Widmer J, Bovier P, Karege F, Raffin Y, Hilleret H, Gaillard JM and Tissot R: Evolution of blood magnesium, sodium and potassium in depressed patients followed for three months. Neuropsychobiology 1992, 26:173-179.
26. Widmer J, Stella N, Raffin Y, Bovier P, Gaillard JM, Hilleret H and Tissot R: Blood magnesium, potassium, sodium, calcium and cortisol in drug-free depressed patients. Magnes Res 1993, 6:33-41.
27. Widmer J, Henrotte JG, Raffin Y, Bovier P, Hilleret H and Gaillard JM: Relationship between erythrocyte magnesium, plasma electrolytes and cortisol, and intensity of symptoms in major depressed patients. J Affect Disord 1995, 34:201-209.
28. Horton R and Biglieri EG: Effect of Aldosterone on the Metabolism of Magnesium. J Clin Endocrinol Metab 1962, 22:1187-1192.
29. Charlton JA and Armstrong DG: The effect of an intravenous infusion of aldosterone upon magnesium metabolism in the sheep. Q J Exp Physiol 1989, 74:329-337.
30. Altamura AC and Morganti A: Plasma renin activity in depressed patients treated with increasing doses of lithium carbonate. Psychopharmacologia 1975, 45:171-5.
31. Hullin RP, Jerram TC, Lee MR, Levell MJ and Tyrer SP: Renin and aldosterone relationships in manic depressive psychosis. Br J Psychiatry 1977, 131:575-81.
32. Holsboer F, Dorr HG and Sippell WG: Blunted aldosterone response to dexamethasone in female patients with endogenous depression. Psychoneuroendocrinology 1982, 7:155-162.
33. Antonijevic IA, Murck H, Frieboes RM, Barthelmes J and Steiger A: Sexually dimorphic effects of GHRH on sleep-endocrine activity in patients with depression and normal controls - part I: the sleep EEG. Sleep Research Online 2000, 3:5-13.
34. Steiger A, von Bardeleben U, Wiedemann K and Holsboer F: Sleep EEG and nocturnal secretion of testosterone and cortisol in patients with major endogenous depression during acute phase and after remission. J Psychiatr Res 1991, 25:169-177.
35. Thase ME, Kupfer DJ, Fasiczka AJ, Buysse DJ, Simons AD and Frank E: Identifying an abnormal electroencephalographic sleep profile to characterize major depressive disorder. Biol Psychiatry 1997, 41:964-973.
36. Brandenberger G, Charifi C, Muzet A, Saini J, Simon C and Follenius M: Renin as a biological marker of the NREM-REM sleep cycle: effect of REM sleep suppression. J Sleep Res 1994, 3:30-35.
37. Charloux A, Gronfier C, Lonsdorfer-Wolf E, Piquard F and Brandenberger G: Aldosterone release during the sleep-wake cycle in humans. Am J Physiol 1999, 276:E43-E49.
38. Held K, Antonijevic IA, Künzel H, Uhr M, Wetter TC, Golly IC, Steiger A and Murck H.: Oral Mg 2+ supplementation reverses age-related neuroendocrine and sleep EEG changes in humans. Pharmacopsychiatry 2002, 35:135-143.
39. Rechtschaffen A and Kales A: A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. 1968. US Department of Health, Education & Welfare, Neurological Information Network Bethesda, MD
40. Holsboer F, Dorr HG and Sippell WG: Blunted aldosterone response to dexamethasone in female patients with endogenous depression. Psychoneuroendocrinology 1982, 7:155-162.
41. Vieweg WV, Veldhuis JD and Carey RM: Temporal pattern of renin and aldosterone secretion in men: effects of sodium balance. Am J Physiol 1992, 262:871-877.
42. Armitage R, Hoffmann R, Trivedi M and Rush AJ: Slow-wave activity in NREM sleep: sex and age effects in depressed outpatients and healthy controls. Psychiatry Res 2000, 95:201-213.
43. Lauer C, Riemann D, Wiegand M and Berger M: From early to late adulthood. Changes in EEG sleep of depressed patients and healthy volunteers. Biol Psychiatry 1991, 29:979-993.
44. Murck H: Atypical depression spectrum disorder - neurobiology and treatment. Acta Neuropsych 2003, 15:227-241.
45. Antonijevic IA, Murck H, Frieboes RM, Holsboer F and Steiger A: On the gender differences in sleep-endocrine regulation in young normal humans. Neuroendocrinology 1999, 70:280-287.
46. Garcia MJ, Martinez-Martos JM, Mayas MD, Carrera MP and Ramirez-Exposito MJ: Hormonal status modifies renin-angiotensin system-regulating aminopeptidases and vasopressin-degrading activity in the hypothalamus-pituitary-adrenal axis of male mice. Life Sci 2003, 73:525-538.
47. Shricker K, Holmer S, Kramer BK, Riegger GA and Kurtz A: The role of angiotensin II in the feedback control of renin gene expression. Pflügers Arch 1997, 434:166-172.
48. Murck H: Magnesium and affective disorders. Nutr Neurosci 2002, 5:375-89.
49. Stella A, Macchi A, Genovesi S, Centonza L and Zanchetti A: Angiotensin converting enzyme inhibition and renin release from the kidney. J Hypertens Suppl 1989, 7:S21-S25.
50. Grazzini E, Boccara G, Joubert D, Trueba M, Durroux T, Guillon G, Gallo-Payet N, Chouinard L, Payet MD and Serradeil Le Gal C: Vasopressin regulates adrenal functions by acting through different vasopressin receptor subtypes. Adv Exp Med Biol 1998, 449:325-334.
51. Keck ME, Welt T, Müller MB, Uhr M, Ohl F, Wigger A, Toschi N, Holsboer F and Landgraf R.: Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology 2003, 28 :235-243.
52. Csukas S, Hanke CJ, Rewolinski D and Campbell WB: Prostaglandin E2-induced aldosterone release is mediated by an EP2 receptor. Hypertension 1998, 31:575-581.
53. Lieb J, Karmali R and Horrobin DF: Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostaglandins Leukot Med 1983, 10:361-367.
54. Murck H, Song C, Horrobin DF and Uhr M: Ethyl-EPA and dexamethasone-resistance in therapy-refractory depression. . Submitted
55. Schmiedek P, Sadee W and Baethmann A: Cerebral uptake of a 3 H-labelled spirolactone compound in the dog. Eur J Pharmacol 1973, 21:238-41.
56. Uhr M, Holsboer F and Müller MB: Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J Neuroendocrinol 2002, 14:753-9.
57. Müller MB, Keck ME, Binder EB, Kresse AE, Hagemeyer TP, Landgraf R, Holsboer F and Uhr M.: ABCB1 (MDR1)-Type P-Glycoproteins at the Blood-Brain Barrier Modulate the Activity of the Hypothalamic-Pituitary-Adrenocortical System: Implications for Affective Disorder. Neuropsychopharmacology 2003. doi:101038/sj.npp.1300257
58. Pariante CM, Makoff A, Lovestone S, Feroli S, Heyden A, Miller AH and Kerwin RW: Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br J Pharmacol 2001, 134:1335-43.
59. Bello-Reuss E, Ernest S, Holland OB and Hellmich MR: Role of multidrug resistance P-glycoprotein in the secretion of aldosterone by human adrenal NCI-H295 cells. Am J Physiol Cell Physiol 2000, 278:1256-1265.
60. Nemeroff CB and O'Connor CM: Introduction: Depression as a risk factor for cardiovascular and cerebrovascular disease: Emerging data and clinical perspectives. Am Heart J 2000, 140:55-56.
61. Weber-Hamann B, Hentschel F, Kniest A, Deuschle M, Colla M, Lederbogen F and Heuser I: Hypercortisolemic depression is associated with increased intra-abdominal fat. Psychosom Med 2002, 64:274-277.